Trial
NCT00330668
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ipsen
Collaborators
—
Condition
Growth Disorders
Intervention
rh IGF-1 (mecasermin)
Why stopped
Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-14